PILGRIM
Preventing community and nosocomial spread and infection with MRSA ST 398 - instruments for accelerated control and integrated risk management of antimicrobial resistance
| Coordinatore | THE ROYAL VETERINARY COLLEGE
Organization address
address: Royal College Street contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 3˙727˙953 € |
| EC contributo | 2˙993˙824 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-FP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2011-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE ROYAL VETERINARY COLLEGE
Organization address
address: Royal College Street contact info |
UK (LONDON) | coordinator | 0.00 |
| 2 |
ACCELOPMENT AG
Organization address
address: SEEFELDSTRASSE 198 contact info |
CH (ZUERICH) | participant | 0.00 |
| 3 |
AGUACURE LIMITED
Organization address
address: ALUN ROBERTS BUILDING 9THE FLOOR contact info |
UK (BANGOR) | participant | 0.00 |
| 4 |
CENTRUM VOOR ONDERZOEK IN DIERGENEESKUNDE EN AGROCHEMIE - CODA
Organization address
address: Groeselenberg 99 contact info |
BE (BRUXELLES) | participant | 0.00 |
| 5 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 0.00 |
| 6 | KOBENHAVNS UNIVERSITET | DK | participant | 0.00 |
| 7 |
RIJKSINSTITUUT VOOR VOLKSGEZONDHEIDEN MILIEU*NATIONAL INSTITUTEFOR PUBLIC HEALTH AND THE ENVIRONMENTEN
Organization address
address: Antonie Van Leeuwenhoeklaan 9 contact info |
NL (BILTHOVEN) | participant | 0.00 |
| 8 |
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
Organization address
address: Cranmer Terrace contact info |
UK (LONDON) | participant | 0.00 |
| 9 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 0.00 |
| 10 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 0.00 |
| 11 |
UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
BE (BRUXELLES) | participant | 0.00 |
| 12 |
VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
Organization address
address: TECHNICKA 5 contact info |
CZ (PRAHA 6) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Methicillin-resistant Staphylococcus aureus (MRSA) are of increasing concern both as community- and hospital-acquired pathogens. Since 2005, a specific clone, MRSA ST398 is spreading both in livestock populations and occupationally-exposed people resulting in human infection and disease in several EU Member States. The key objective of the PILGRIM project is to provide a range of novel control measures for the accelerated identification and control of emerging resistant bacteria. In order to achieve these we will undertake epidemiological and physiological studies of MRSA ST398 and use molecular approaches in well comparable animal models as well as humans in community and healthcare settings to 1) investigate/explore its biology and ecology, 2) identify and characterise factors determining the transmission pathways and risk from animal to human and between humans, 3) establish genetic differences, host-range and virulence of adhesive and non-adhesive strains as well as differences between ST398 and other MRSA, 3) identify specific genes for the development of new rapid tests to identify specific MRSA strains, 4) provide a Technology Testing Platform for developing and assessing decolonisation and environmental sanitation approaches, 5) integrate results in policy and practice guidelines. This project brings together clinical, genetic, microbiological and public health partners from 6 European countries, internationally renowned for their expertise in complementary ecosystems research. The two SME partners ensure the exploitation of results and the knowledge transfer, enabling associated companies to bring validated solutions to the market. The PILGRIM research will facilitate rapid and cost-effective measures to combat emerging resistant strains in order to prevent and eradicate community and nosocomial infections for better protection of citizens and patients in Europe and beyond.'